TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06602180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular PNF technique, (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT).
Description: Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments.~Scapular PNF:~Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~TAPA involves an intervention protocol composed of:~10-min neuro dynamics oriented to the activity 10-min proprioceptive neuromuscular facilitation activities. 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular PNF technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT))
Description: Proprioceptive Neuromuscular Facilitation (PNF) is treatment approach that focus on motor learning, helps the patient to relax, improves coordination, and normalizes the motion. The repeated contractions technique increases active range of motion and strength and guides the patient's motion towards the desired motion,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity-Oriented Antiedema Proprioceptive Therapy (TAPA) technique for the affected shoulder region plus conventional physiotherapy program in a form of (Complex decongestive therapy (CDT)
Description: Activity-Oriented Proprioceptive Antiedema Therapy TAPA:~TAPA involves an intervention protocol composed of:~* 10-min neuro dynamics oriented to the activity~* 10-min proprioceptive neuromuscular facilitation activities.~* 10-min proprioceptive anti-edema bandaging, including patient and/or caretaker instructions for placement, as well as assistance on techniques to use for performing everyday activities,~Complex or combined decongestive physical therapy (CDT):~skin care and patient education, manual lymphatic drainage MLD, joints exercises, and compression garments
Study: NCT06605417

Intervention type: GENETIC
Intervention: Methylomics
Description: Methylomics analysis of FFPE blocks and frozen tissues

Intervention type: GENETIC
Intervention: Methylomics
Description: Methylomics analysis of FFPE blocks and frozen tissues

Intervention type: GENETIC
Intervention: RNA sequencing
Description: RNA sequencing of FFPE blocks and frozen tissues

Intervention type: GENETIC
Intervention: RNA sequencing
Description: RNA sequencing of FFPE blocks and frozen tissues

Intervention type: GENETIC
Intervention: Spatial transcriptomics
Description: Spatial transcriptomics of FFPE blocks and frozen tissues

Intervention type: GENETIC
Intervention: Spatial transcriptomics
Description: Spatial transcriptomics of FFPE blocks and frozen tissues
Study: NCT03915678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association atezolizumab + BDB001 + RT
Description: A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association atezolizumab + BDB001+ RT
Description: A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association atezolizumab + BDB001+ RT
Description: A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.
Study: NCT06605417

Intervention type: GENETIC
Intervention: Liquid biopsy
Description: cfDNA characterization extracted from blood/saliva

Intervention type: GENETIC
Intervention: Liquid biopsy
Description: cfDNA characterization extracted from blood/saliva
Study: NCT06605521

Intervention type: PROCEDURE
Intervention: Subclavian lymph node dissection+radiotherapy
Description: The patient grouping is determined jointly by the researchers and participants, and patients in Group A are selected for supraclavicular lymph node dissection and radiotherapy.

Intervention type: PROCEDURE
Intervention: Simple clavicular region radiotherapy
Description: If the patient chooses Group B treatment plan, they will receive simple clavicle area radiotherapy.
Study: NCT06604975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of Basal Copeptin level
Description: Copeptin test is performed after solid fasting since midnight without water restriction. After blood collection on heparin tube used for biological inclusion criteria, heparinized plasma is transferred to Timone University hospital (transport temperature +4°C) for screening copeptin assay.~The basal copeptin level determines the next step:~1. copeptin ≥ 30 pmol/L defines the diagnosis of NDI and results in a specific care;~2. copeptin \&lt; 30 pmol/L defines the group of eligible patients for arginine stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of arginine-stimulated copeptin
Description: The arginine-stimulated copeptin test start at 8 am, after solid fasting since midnight without water restriction, and 30 min of rest in decubitus position. A dose of 0.5 g/kg of arginine (maximum 40g) diluted in 0.9% NaCl is infused over 30 min through a peripheral venous line. Copeptin is measured at T0 (before infusion), T45, T60, T90, and T120 min after infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IRM
Description: Based on our previous study, patients with basal copeptin value over 3.53 pmol/L are considered as positive diagnosis of PP (Se 100%, Sp 87.4%) and cerebral MRI is not performed for this group of patients (PP group).~A cerebral and pituitary MRI performed according to reference procedures (without and with contrast medium used in routine care) for patients considered as an uncertain diagnosis (UD) based on basal copeptin value (\&amp;lt; 3.53 pmol/L). MRI interpretation is performed by two independent neuroradiologists (one from the recruiting center and one from the pilot center). In case of discrepancies, a third independent interpretation will be performed by a neuroradiologist from the coordinating center. Abnormal pituitary MRI (thickened pituitary stalk pituitary tumor, ectopic neurohypophysis, septo-optic dysplasia, empty sellar, Rathke pouch) allows a diagnosis of CDI leading to etiological investigations and AVP treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water reduction at home
Description: Patients with basal copeptin ≥ 3.53 pmol/l (PP group), and UD patients with normal MRI have gradual reduction of water intake at home without AVP treatment : gradual reduction with 20% in the first week, 30% in the second, 40% in the third, reaching 50% of daily fluid in the last week including restriction overnight, deletion drink before sleep. Some recommendations will be provided to help physicians. For all these latest patients, a clinical reassessment (weight, height, heart rate, blood pressure, input/output 24 hours balance) is performed one month later.
Study: NCT06606067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg daily 2 weeks before surgery and 1 week after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily
Study: NCT06606704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Bolus 5
Description: (Serving 1: 5 grams of creatine + 3 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Bolus 3
Description: (Serving 1: 3 grams of creatine + 5 grams of placebo in the morning; Serving 2: 8 grams of placebo at least 6 hours after Serving 1).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Intermittent 5
Description: (Serving 1: 2.5 grams of creatine + 5.5 grams of placebo in the morning, Serving 2: 2.5 grams of creatine + 5.5 grams of placebo at least 6 hours after Serving 1).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (Serving: 8 grams of placebo in the morning; Servings 2: 8 grams of placebo at least 6 hours after Serving 1).
Study: NCT06606730

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Administration of pembrolizumab for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deescalation
Description: Patients will be followed up according to standard practice for 4 years
Study: NCT06608706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) for psychosis
Description: EMDR aims to treat and process trauma by safely retrieving the trauma memories while taxing the working memory. EMDR targets trauma symptoms through memory reprocessing of traumatic memories, and consists of eight flexible phases: history taking/case conceptualization; preparation for memory reprocessing; assessment/identification of a target memory; desensitization/reprocessing; installation of positive cognition; body scan; closure; and re-evaluation. EMDR in the current trial has psychosis-specific adaptations including focus on psychoeducation, preparation for reprocessing and patient safety. Techniques targeting dissociation, psychotic symptoms and psychosis-related challenges are included.
Study: NCT06607432

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Interference Stimulation (tIS)
Description: Field strength dose of 0.30 - 0.40 V/m

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Interference Stimulation (tIS)
Description: Field strength dose of 0.30 - 0.40 V/m

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Interference Stimulation (tIS)
Description: Field strength dose of 0.30 - 0.40 V/m

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham tIS
Description: Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham tIS
Description: Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
Study: NCT03915678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association atezolizumab + BDB001 + RT
Description: A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association atezolizumab + BDB001 + RT
Description: A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Association atezolizumab + BDB001 + RT
Description: A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~BDB001 will be administered by a 30-minute intravenous infusion before atezolizumab, on Days 1, 8, and 15 of cycles 1, 2, and 3. Then from cycle 4 BDB001 will be administered on Day 1 every 3 weeks.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration. All participants will be treated by high dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy.
Study: NCT06268782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitate your core
Description: The intervention was an online exercise program \&#34;Rehabilitate your core,\&#34; designed for postpartum women by a company called Nordic Fit Mama. Its primary goal is to fortify the core and pelvic floor muscles to enhance the recovery process after childbirth, while also emphasizing overall well-being. The program is accessible through a website and is intended to be completed independently over a span of 6 weeks. Each week focuses on a specific theme, encompassing six to seven subtopics. The regimen follows a progressive structure, starting with the identification of pelvic floor and core muscles and gradually advancing to exercises aimed at strengthening them. The exercises, which last around 10 minutes each, are tailored to integrate seamlessly into daily life. Comprising 25 instructional exercise videos and 13 guidance videos, the program only necessitates access to a device for logging into the platform.
Study: NCT06297057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurophysiological Recordings
Description: Eyes-open resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes open and staring at a white cross in the center of a light grey screen to limit their eye movements.~Eyes-closed resting-state blocks: these blocks will last 5 minutes each. Subjects will be asked to relax and not think about anything specific, keeping their eyes closed.~ASSR: this block will last approximately 6 minutes. Stimuli will consist of a train of sounds presented repeatedly at high frequency.~MMN: this block will last approximately 3 minutes. Stimuli will consist of a train of equal sounds presented alternating with a 'deviant' (rarer frequency) sound.
Study: NCT05306860

Intervention type: OTHER
Intervention: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
Description: No intervention was applied to the groups the samples will be collected in terms of the diagnosis (periodontitis, healthy)
Study: NCT06132009

Intervention type: PROCEDURE
Intervention: Surgery of endometriosis
Description: Cystectomy or unilateral oophorectomy due to endometriosis

Intervention type: PROCEDURE
Intervention: Surgery of endometriosis
Description: Cystectomy or unilateral oophorectomy due to endometriosis
Study: NCT05316259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-16350
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-16350
Description: Administered orally
Study: NCT06607432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham tIS
Description: Sham transcranial interferential stimulation. Sham comparator to be administered to all groups.
Study: NCT06606353

Intervention type: BEHAVIORAL
Intervention: Talk-To-Jo
Description: Participation begins with the completion of a socio-demographic questionnaire. Next, participants test the Talk-to-Jo intelligent digital health companion on a tablet: first, a member of the research team explains the tool to the dyad (person with a neurocognitive disorder and their caregiver). The person with the disorder then interacts with Talk-to-Jo, possibly with the help of their caregiver. An observer is present, but does not intervene unless there are questions or technical problems. At the end of the test, health recommendations are given. Questions focus on the participant's memory and depression.~Next, a 30-minute interview is conducted with a member of the research team to gather impressions of the tool, digital skills, barriers and facilitators to using AI, as well as your expectations of Talk-to-Jo.~An additional individual interview can be arranged if required.
Study: NCT06425224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tens therapy
Description: There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tens therapy
Description: There will be 3 weekly therapy sessions for 12 continuous weeks, lasting 30 minutes each. 20 Hertz with a pulse width of 200 µsec will be administered in each session. The intensity will be applied to each patient depending on individual tolerance. TENT therapy will be performed as follows:~1. The active electrode (cathode - red) is placed and adhered 3 - 5 cm above the internal malleolus and 1 cm behind the tibia.~The second reference electrode (anode - black) is attached to the calcaneus.~The equipment must previously be programmed under the following parameters:~Continuous current Frequency: 20 Hz. Pulse width: 200 µsec Time: 30 min. Intensity: to the patient's tolerance, gross motor perception to verify correct application, upon reaching it, increase the intensity to clearly sensory activation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapoxetine placebo
Description: Patients in this group will receive dapoxetine placebo (capsules with only excipients without active ingredient) as needed, taken 3 to 4 hours before sexual intercourse during the 12 weeks of the intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (dapoxetine 30 mg as needed)
Description: Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment (dapoxetine 30 mg as needed)
Description: Patients in this group will receive dapoxetine 30 mg, taken 3 to 4 hours before sexual intercourse, for the 12 weeks of the study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo therapy
Description: In addition to the medication, patients will receive three weekly sessions of placebo therapy for twelve continuous weeks, lasting 30 minutes each. For this, the black electrode will be placed on the external malleolus and the red one 4 finger widths towards the head on the lateral edge of the tibia. 20 Hertz with a pulse width of 200 µsec will be administered in each session.
Study: NCT06268093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 50 - 200 mg once at nightime
Study: NCT05311332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin
Description: Augmentation of horizontal deficient anterior maxilla using the conventional protocol of cortical shell technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Augmentation of horizontal deficient anterior maxilla with a cortical shell harvested from a chin using patient specific surgical guide then positioned with another guide
Description: using a patient-specific surgical guide to harvest bone cortical shell from the chin and another patient-specific surgical guide to fix it in the atrophied maxillary anterior area
Study: NCT06608992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SURGICEL® Powder
Description: SURGICEL® Powder are hemostatic product made of compacted, regenerated oxidized cellulose fine fiber aggregates, produced using a patented process. These particles are pre-loaded into an applicator device for application to the target bleeding site. SURGICEL® Powder are white with a slight yellow tint and have a faint caramel-like scent.When SURGICEL® Powder are fully saturated with blood, they expand into a brown or black gel-like substance that helps form a blood clot. This substance acts as a hemostatic adjunct to control localized bleeding.
Study: NCT06605911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical triamcinolone acetonide
Description: ten patients with OLP were received topical triamcinolone acetonide four times per day for six weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Curcumin
Description: Ten patients with OLP received topical curcumin four times per day for six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical triamcinolone acetonide combiend with topical curcumin
Description: Ten patients with OLP received a combination of topical triamcinolone acetonide and topical curcumin four times per day for six weeks.